🇺🇸 FDA
Patent

US 10279015

TPP-1 formulations and methods for treating CLN2 disease

granted A61KA61K38/4813A61K47/02

Quick answer

US patent 10279015 (TPP-1 formulations and methods for treating CLN2 disease) held by BIOMARIN PHARMACEUTICAL INC. expires Mon May 02 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
BIOMARIN PHARMACEUTICAL INC.
Grant date
Tue May 07 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 02 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
25
CPC classes
A61K, A61K38/4813, A61K47/02, A61K9/0048, A61K9/0085